Cellectis ADR (CLLS) — Titan Protect Analysis

CLLS

Cellectis ADR

Healthcare · ·

$3.06

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$318M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.10

Based on estimated future earnings — lower means cheaper

Rev Growth

-37.3%

Year-over-year revenue change

Profit Margin

-89.5%

How much profit the company keeps from each dollar of revenue

ROE

-76.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$8.00

+161% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 5 analysts covering this stock

About Cellectis ADR

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence,

https://www.cellectis.com

Country: France Employees: 224 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.478

Positive but modest risk-adjusted returns

Kelly Fraction

0.0154

Marginal edge — very small allocation suggested

Calmar Ratio

0.129

Drawdown risk outweighs the returns — higher risk profile

Annual Return

7.5%

Historical annualised return based on price data

Max Drawdown

-57.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.72

Significantly more volatile than the market

52W High

$5.48

44% below the year high

52W Low

$1.33

131% above the year low

Avg Volume

40,238

Average daily shares traded — higher means easier to buy and sell

Short Ratio

14.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.67

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

137.41

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-333.4%

Profit from core operations before interest and tax

Free Cash Flow

$91M

Positive — the business generates more cash than it spends

Revenue (TTM)

$75M

Total revenue over the last 12 months

Net Income

$-67,230,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$8.00

Target Low

$4.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go